Monday, February 16, 2026 2/16/2026

The Carolina Endometrial Cancer Study: A population-based survivor cohort

Award Number: U01CA281026
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2024
PERIOD OF PERFORMANCE END DATE: 02/28/2029

Group Awards By:

View Award Description

The Carolina Endometrial Cancer Study: A population-based survivor cohort - Endometrial cancer is the 4th most common cancer diagnosed and 6th leading cause of cancer death among United States (U.S.) women. Today, there are more than 891,000 endometrial cancer survivors in the U.S., making it the second largest cancer survivor group among women (after breast). Black women are more likely than White women to have endometrial cancer recur and are twice as likely to die. Disparities in endometrial cancer outcomes are multifactorial; contributors likely include, but are not limited to, higher prevalence of worse-prognosis biologic subtypes, variation in symptom recognition and receipt of guideline-concordant cancer treatment, and differential survivorship care. We propose a comprehensive approach to understanding endometrial cancer outcomes within a population-based survivorship cohort. The Carolina Endometrial Cancer Study (CECS) will prospectively recruit women with newly diagnosed endometrial cancer in North Carolina using the statewide Central Cancer Registry’s rapid case ascertainment program. Within the planned cohort of ~1,700 women, we aim to enroll ~667 Black women. Baseline data collection includes retrieval of tumor paraffin blocks and medical records for detailed diagnostic and treatment history, collection of buccal samples, and administration of questionnaires offered in written, phone, or online formats. We will conduct follow-up interviews every 18 months and retrieve medical records for any additional endometrial cancer treatment or reported disease recurrence. Our aims include: 1) To assess variation in the distribution of endometrial cancer histologic and molecular subtypes that are associated with poor prognosis among Black and White women evaluated by centralized pathology review; 2) To assess variation in presenting symptoms and receipt of guideline-concordant endometrial cancer treatment among Black and White women and; 3) To assess variation in experience and provider assessment of guideline-recommended symptoms for surveillance visits and survivorship care among Black and White women. The proposed cancer epidemiology survivorship cohort uses a population-based platform and combines detailed tumor biology and patient-reported survey data to investigate endometrial cancer biology, medical care, and experience. We collect detailed information on individual-level molecular tumor characteristics; behavioral and lifestyle factors; cancer treatment, follow-up care, and recurrence information abstracted from medical records; and have an established infrastructure to link participant records to administrative insurance claims and area-level social determinants of health and health system factors. The multidisciplinary investigative team and patient advocacy support facilitate investigation of not only the proposed aims, but create a resource and infrastructure for ongoing research to advance the science of endometrial cancer survivorship.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $566,937 )
2026	2026	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Cause and Prevention Research	001	3	1/29/2026	NON-COMPETING CONTINUATION	$566,937
2026	2025	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Cause and Prevention Research	000	2	1/29/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $566,937

Issue Date FY: 2025 ( Subtotal = $637,806 )
2025	2025	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Cause and Prevention Research	002	2	5/22/2025	NON-COMPETING CONTINUATION	$63,779
2025	2025	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Cause and Prevention Research	001	2	2/13/2025	NON-COMPETING CONTINUATION	$574,027
2025	2024	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Cause and Prevention Research	000	1	1/15/2025	NEW	$0
														Subtotal = $637,806

Issue Date FY: 2024 ( Subtotal = $659,174 )
2024	2024	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Cause and Prevention Research	000	1	2/19/2024	NEW	$659,174
														Subtotal = $659,174

Grand Total All Awards = $1,863,917

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The Carolina Endometrial Cancer Study: A population-based survivor cohort

Award Number: U01CA281026

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2024

PERIOD OF PERFORMANCE END DATE: 02/28/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer